Every planning season produces the same quiet moment. The forecasts are built, the templates have gone around twice, and...
Isotope analysis is moving beyond specialised laboratories towards broader, molecular-level applications. In this BioSpe...
EVENT WRAP-UP | ASIA BIO PARTNERING FORUM 2026 A forum that met the moment Some conferences describe the industry. The...
"Almost every company preparing for a partnering conversation prepares for the wrong gate. The rejection usually happens...
Before we discuss the market, can you tell us about your role and what drew you to this area of healthcare logistics? I...
A session billed as a conversation about partnering was, on closer inspection, something rather more useful: a pricing s...
The most useful thing about an opening plenary is usually not what gets said. It is who the organisers decided to put on...
Biopharmaceutical manufacturing is entering a period of significant change. With over 2000 biological therapeutics in de...
Rare diseases/orphan diseases affect a very small fraction of the population and are frequently debilitating. World Heal...
The global AI debate is often framed as a choice between acceleration and restraint: innovate first and regulate later, ...
Please share details of the current R&D projects of DNDi in India. What challenges are these projects addressing? O...
What are Caidya’s major highlights for 2026 that will strengthen its presence in the global CRO market? And what a...
How will the new investment accelerate the development of TAVST01? When do you plan to launch the product in the market?...
As healthcare systems across Southeast Asia embrace smarter technologies and new models of care, Taiwan is looking to de...
China’s biotech and pharmaceutical sector is entering a new phase of global relevance. A surge in out-licensing de...
How is Takeda’s partnership with Biological E. Limited playing a role in strengthening dengue vaccine access in In...
As cell therapies advance towards greater clinical sophistication and commercial scale, the focus is shifting fr...
In conversation with BioSpectrum Asia, Laurie Masiello and John Masiello, Co-Founders of Predictive Monitor, explore how...
Australia is rapidly evolving beyond its reputation as a destination for early-stage clinical trials to build a more com...
BIOSPECTRUM ASIA | EARNINGS ALERTS +35.2% 10.7 pt -15% EUR 0.15 Celltrion r...
How are Australia–India health partnerships driving innovations in the non-communicable diseases sector? We have ...
For decades, cancer treatment has largely focused on finding a single breakthrough therapy capable o...
On 29 September, the second compliance date under Proclamation 11020 arrives. From that moment, every pharmaceutical imp...
Healthcare delivery is undergoing structural reconfiguration. What began as a tactical response to hospital capacity pre...
The Asia-Pacific (APAC) region is entering a transformative era in cancer research. Governments are investing heavily in...
